Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07470489) titled 'A Multi-Center Single-Arm Phase 2 Trial Of Zanzalintinib In Combination With Cemiplimab In BRAF Wild-Type Anaplastic Thyroid Cancer: The ZEPHYR Trial' on March 9.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Anaplastic Thyroid Cancer
Intervention:
Drug: Cemiplimab
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 30, 2026
Target Sample Size: 12
Countries of Recruitment:
United States
To know more, ...